Who Pays My Doctor?

Healthcare provider profile · identity verified

John Martin Vaeth, MD

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · BALTIMORE, MD · NPI 1992848345

Profile state: payments only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show John Martin Vaeth, MD received $465,679.33 in general payments during 2025 across 578 reported records.

ABBVIE INC. accounted for 33.5% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 6 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$465,679.33

578 reported records · 8 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
ABBVIE INC. Unresolved — no canonical attribution shown $155,917.2833.5%2062025
Axsome Therapeutics, Inc. Unresolved — no canonical attribution shown $128,273.4427.6%1672025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Unresolved — no canonical attribution shown $112,455.1424.1%1242025
Vanda Pharmaceuticals Inc. Unresolved — no canonical attribution shown $50,874.8510.9%632025
Otsuka America Pharmaceutical, Inc. Unresolved — no canonical attribution shown $18,056.363.9%142025
Otsuka Pharmaceutical Development & Commercialization, Inc. Unresolved — no canonical attribution shown $59.520.0%22025
Tris Pharma Inc Unresolved — no canonical attribution shown $27.110.0%12025
Lundbeck LLC Unresolved — no canonical attribution shown $15.630.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program$261,495.50100
Honoraria$106,425.0037
Travel and Lodging$82,814.05273
Food and Beverage$11,424.78167
Consulting Fee$3,520.001

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
VRAYLAR
Normalized: vraylar		 Drug ABBVIE INC. $150,222.18 198 2025
Source payment records
Auvelity
Normalized: auvelity		 Drug Axsome Therapeutics, Inc. $128,273.44 167 2025
Source payment records
CAPLYTA
Normalized: caplyta		 Drug ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $112,455.14 124 2025
Source payment records
FANAPT
Normalized: fanapt		 Drug Vanda Pharmaceuticals Inc. $50,874.85 63 2025
Source payment records
REXULTI
Normalized: rexulti		 Drug Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. $18,106.99 16 2025
Source payment records
Dyanavel XR
Normalized: dyanavel xr		 Drug Tris Pharma Inc $27.11 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $465,679.33 · 578 records ABBVIE INC. Auvelity, CAPLYTA, Dyanavel XR, FANAPT, REXULTI, VRAYLAR — —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error